Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer Chemotherapy and Pharmacology
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2015

01.04.2015 | Original Article

Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer

verfasst von: Yu-Wen He, Mei-Ling Zhao, Xin-Yun Yang, Jun Zeng, Qiu-Hua Deng, Jian-Xing He

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recent clinical trials showed that expression of excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and thymidylate synthase (TS) proteins was able to predict the effects of non-small cell lung cancer (NSCLC) to chemotherapy. However, it remains unknown whether the adjuvant chemotherapy based on expression of the three proteins has survival significance in Chinese NSCLC patients.

Methods

We investigated 128 Chinese patients receiving chemotherapy after tumor resection for expression of these proteins using immunohistochemistry. Based on protein expression, patients were assigned to two groups for different adjuvant chemotherapy regimes. The disease-free survival (DFS) data were collected and analyzed using Kaplan–Meier curves and Cox models.

Results

We found that DFS of these patients with carboplatin and a third-generation agent (gemcitabine or pemetrexed) stratified by protein expression showed no statistical difference between individual treatment versus non-individuation treatment analyzed using Kaplan–Meier method (P = 0.143, median 23.9 vs. 30.8 months). Furthermore, the multivariate analysis showed that histology and tumor stages were independent predictors for DFS in these patients.

Conclusions

The results suggest that chemotherapy based on ERCC1, RRM1, and TS expression did not have significant impact on DFS of patients with resection of NSCLC.
Literatur
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed
2.
McCloskey P, Balduyck B, Van Schil PE, Faivre-Finn C, O’Brien M (2013) Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer 49(7):1555–1564CrossRefPubMed
3.
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative G (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4):351–360CrossRefPubMed
4.
Geiger S, Schlemmer M, Heinemann V, Stemmler HJ (2010) Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all? Anticancer Drugs 21(9):799–804CrossRefPubMed
5.
Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Pechoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T (2010) Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 28(1):35–42CrossRefPubMed
6.
Filipits M, Pirker R (2011) Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer 74(3):355–363CrossRefPubMed
7.
Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8(5):582–586PubMed
8.
Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer G (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10(4):1318–1325CrossRefPubMed
9.
Rouquette I, Mazieres J (2011) A brief overview of a lung cancer biomarker: thymidylate synthase. Rev Mal Respir 28(6):773–777CrossRefPubMed
10.
Yokomise H, Liu D, Chang S, Go T, Ishikawa S, Misaki N, Nakashima N (2013) Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery. Anticancer Res 33(3):1107–1115PubMed
11.
Bergot E, Levallet G, Campbell K, Dubois F, Lechapt E, Zalcman G (2013) Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. Eur Respir Rev 22(130):565–576CrossRefPubMed
12.
Passaro A, Palazzo A, Trenta P, Mancini ML, Morano F, Cortesi E (2012) Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. Curr Med Chem 19(22):3689–3700CrossRefPubMed
13.
Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98(9):1336–1343CrossRefPubMed
14.
Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, Investigators IB (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991CrossRefPubMed
15.
Nicolson MC, Fennell DA, Ferry D, O’Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, Andre V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM (2013) Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol 8(7):930–939CrossRefPubMed
16.
Shimizu T, Nakanishi Y, Nakagawa Y, Tsujino I, Takahashi N, Nemoto N, Hashimoto S (2012) Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res 32(10):4589–4596PubMed
17.
Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR (2013) Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 31(19):2404–2412CrossRefPubMedCentralPubMed
18.
Besse B, Olaussen KA, Soria JC (2013) ERCC1 and RRM1: ready for prime time? J Clin Oncol 31(8):1050–1060CrossRefPubMed
19.
De Dosso S, Zanellato E, Nucifora M, Boldorini R, Sonzogni A, Biffi R, Fazio N, Bucci E, Beretta O, Crippa S, Saletti P, Frattini M (2013) ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother Pharmacol 72(1):159–165CrossRefPubMed
20.
Hubner RA, Riley RD, Billingham LJ, Popat S (2011) Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One 6(10):e25164CrossRefPubMedCentralPubMed
21.
Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, Andre F, Soria JC (2011) Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin Cancer Res 17(17):5562–5572CrossRefPubMed
22.
Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 8(12):e82241CrossRefPubMedCentralPubMed
23.
Lee SH, Noh KB, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kim CH, Kang KH, In KH (2013) Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer 81(1):102–108CrossRefPubMed
24.
Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, Cerny R, Pesek M (2012) Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res 32(11):5003–5010PubMed
25.
Olaussen KA, Mountzios G, Soria JC (2007) ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13(4):284–289CrossRefPubMed
26.
Seyhan EC, Altin S, Cetinkaya E, Sokucu S, Abali H, Buyukpinarbasili N, Fener N (2011) Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma. Ann Thorac Cardiovasc Surg 17(2):110–117CrossRefPubMed
27.
Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127(3):978–983CrossRefPubMed
28.
Sodja E, Knez L, Kern I, Ovcaricek T, Sadikov A, Cufer T (2012) Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer 48(18):3378–3385CrossRefPubMed
29.
Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C, Patumanond J (2013) The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag Res 5:327–336CrossRefPubMedCentralPubMed
30.
Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D (2013) Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Lung Cancer 82(2):324–329CrossRefPubMed
31.
Yan D, Wei P, An G, Chen W (2013) Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. J Cardiothorac Surg 8:149CrossRefPubMedCentralPubMed
32.
Ozdemir O, Ozdemir P, Veral A, Uluer H, Ozhan MH (2013) ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac J Cancer Prev 14(8):4679–4683CrossRefPubMed
33.
Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, Andre F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12):1101–1110CrossRefPubMedCentralPubMed
34.
Friboulet L, Postel-Vinay S, Sourisseau T, Adam J, Stoclin A, Ponsonnailles F, Dorvault N, Commo F, Saulnier P, Salome-Desmoulez S, Pottier G, Andre F, Kroemer G, Soria JC, Olaussen KA (2013) ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. Cell Cycle 12(20):3298–3306CrossRefPubMedCentralPubMed
35.
Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T (2001) Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37(13):1681–1687CrossRefPubMed
36.
Toffart AC, Timsit JF, Couraud S, Merle P, Moro-Sibilot D, Perol M, Mastroianni B, Souquet PJ, Girard N, Jeannin G, Romand P, Chatellain P, Vesin A, Brambilla C, Brambilla E (2014) Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). Lung Cancer 83(2):182–188CrossRefPubMed
37.
Zhang W, Guo N, Yu C, Wang H, Zhang Y, Xia H, Yu J, Lu J (2012) Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma. Tumour Biol 33(6):2209–2216CrossRefPubMedCentralPubMed
38.
Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, Filipits M, Chen Y, Kutok JL, Weaver DT, Ward BE, Soria JC (2012) Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 23(9):2245–2252CrossRefPubMed
Metadaten
Titel
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer
verfasst von
Yu-Wen He
Mei-Ling Zhao
Xin-Yun Yang
Jun Zeng
Qiu-Hua Deng
Jian-Xing He
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2015
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2714-y

Weitere Artikel der Ausgabe 4/2015

Cancer Chemotherapy and Pharmacology 4/2015 Zur Ausgabe

Original Article

A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma

Original Article

Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere

Original Article

Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents

Original Article

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody

Original Article

Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy

Original Article

Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise